Prism Medico & Pharmacy Ltd is Rated Sell

Current Rating and Its Significance

The current Sell rating indicates that MarketsMOJO’s assessment of Prism Medico & Pharmacy Ltd suggests cautiousness for investors considering this stock. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall Mojo Score, which currently stands at 37.0, categorising the stock as a Sell. This score reflects a notable decline from the previous Hold rating, which had a Mojo Score of 53. The change in rating was effected on 18 Nov 2025, but it is essential to understand the stock’s present-day fundamentals and market behaviour as of 02 July 2026.

Quality Assessment: Below Average Fundamentals

As of 02 July 2026, Prism Medico & Pharmacy Ltd exhibits below average quality metrics. The company operates within the Non Banking Financial Company (NBFC) sector but is classified as a microcap, which often entails higher volatility and risk. The firm’s long-term fundamental strength is weak, primarily due to operating losses and poor debt servicing capability. The EBIT to Interest ratio averages at -0.06, signalling that earnings before interest and taxes are insufficient to cover interest expenses, a red flag for financial stability.

Profitability is also subdued, with an average Return on Equity (ROE) of just 0.59%, indicating minimal returns generated on shareholders’ funds. Quarterly results for March 2026 further highlight challenges, with PBDIT (Profit Before Depreciation, Interest and Taxes) at a low of ₹-0.13 crore and PBT (Profit Before Tax) less other income at ₹-0.12 crore. Earnings per share (EPS) also remain negative at ₹-0.40, underscoring the company’s ongoing operational difficulties.

Valuation: Very Expensive Relative to Peers

Despite the weak fundamentals, the stock trades at a premium valuation. The Price to Book Value ratio stands at 2.6, which is considered very expensive compared to the average valuations of its peers in the NBFC sector. This elevated valuation suggests that investors are pricing in expectations of future growth or other positive developments. However, such a premium can also increase downside risk if the company fails to meet these expectations.

Interestingly, the company’s ROE has improved to 2.2% recently, and profits have risen by 38% over the past year. The stock has delivered a remarkable 90.59% return over the last 12 months, reflecting strong market performance despite underlying operational challenges. The PEG ratio of 0.3 indicates that the stock’s price growth is not fully justified by earnings growth, which may caution investors about overvaluation.

Financial Trend: Flat and Challenging

The financial trend for Prism Medico & Pharmacy Ltd remains flat, with no significant improvement in core profitability metrics. The company’s operating losses and weak EBIT to interest coverage ratio highlight ongoing financial stress. While the stock price has appreciated substantially, this has not been matched by commensurate improvements in earnings or cash flow generation. The flat financial grade reflects this disconnect between market performance and fundamental health.

Technical Outlook: Mildly Bullish Momentum

From a technical perspective, the stock shows mildly bullish signals. Recent price movements include a 1-day gain of 1.65%, a 1-week gain of 0.94%, and a 3-month gain of 6.27%. Over the last six months and year-to-date, the stock has surged by 59.61% and 52.47%, respectively. These trends suggest positive investor sentiment and momentum in the market, which may provide some support to the stock price in the near term despite fundamental concerns.

What This Rating Means for Investors

For investors, the Sell rating on Prism Medico & Pharmacy Ltd serves as a cautionary signal. While the stock has demonstrated strong price appreciation recently, the underlying fundamentals remain weak, and the valuation is stretched. The company’s inability to generate consistent profits and service debt effectively raises concerns about its long-term sustainability. Investors should carefully weigh the risks of holding this stock against the potential for further price gains driven by technical momentum.

Those with a lower risk tolerance or seeking fundamentally sound investments may consider reducing exposure or avoiding new positions in this stock. Conversely, investors with a higher risk appetite might monitor the company closely for any signs of fundamental turnaround or valuation correction before making decisions.

Sector and Market Context

Operating within the NBFC sector, Prism Medico & Pharmacy Ltd faces a competitive and regulatory environment that demands strong financial discipline and operational efficiency. The microcap status of the company adds to its risk profile, as smaller companies often experience greater volatility and liquidity constraints. Compared to broader market indices and sector benchmarks, the stock’s recent price gains have outpaced many peers, but this has not been matched by fundamental improvements.

Summary of Key Metrics as of 02 July 2026

To recap, the stock’s key metrics currently stand as follows:

• Mojo Score: 37.0 (Sell)
• Market Capitalisation: Microcap
• Quality Grade: Below Average
• Valuation Grade: Very Expensive (P/B of 2.6)
• Financial Grade: Flat
• Technical Grade: Mildly Bullish
• Return on Equity (ROE): 2.2%
• PEG Ratio: 0.3
• Stock Returns: 1 Year +90.59%, YTD +52.47%, 6 Months +59.61%

These figures illustrate a stock that is currently priced for growth but faces significant fundamental headwinds. Investors should consider these factors carefully when making portfolio decisions.

Looking Ahead

Going forward, the company’s ability to improve its operating profitability and strengthen its balance sheet will be critical to altering its current Sell rating. Monitoring quarterly earnings, debt servicing capacity, and valuation multiples will provide important signals for any potential change in outlook. Until then, the cautious stance reflected in the current rating remains justified based on the available data.

Conclusion

In conclusion, Prism Medico & Pharmacy Ltd’s current Sell rating by MarketsMOJO, last updated on 18 Nov 2025, is supported by a combination of below average quality, expensive valuation, flat financial trends, and only mildly bullish technical indicators as of 02 July 2026. Investors should approach this stock with caution, recognising the risks inherent in its fundamentals despite recent strong price performance.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →